HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is central to these efforts. HeartBeam’s platform is the first cable-free device capable of collecting ECG signals in three non-coplanar directions, synthesizing them into a 12-lead ECG. This enables portable use outside medical facilities, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care.
For business leaders and technology investors, HeartBeam’s progress signals a shift toward decentralized cardiac monitoring, reducing reliance on hospital-based equipment. The company’s AI programs are expected to enhance diagnostic accuracy, potentially lowering healthcare costs and improving patient outcomes. The limited commercial launch for arrhythmia assessment represents the first step toward broader market adoption, with the extended-wear patch and heart attack detection capabilities addressing significant unmet needs in cardiology.
HeartBeam holds over 20 issued patents related to its technology, providing a competitive moat in the emerging remote cardiac monitoring market. The company’s FDA clearances and ongoing development underscore its potential to disrupt traditional ECG systems. As healthcare systems increasingly prioritize remote patient monitoring, HeartBeam’s innovations could become integral to cardiac care management.
Investors and industry observers will closely watch the Q1 2026 earnings call for details on commercial traction, regulatory milestones, and partnership opportunities. The company’s ability to execute its growth initiatives will determine its impact on the cardiac device market, which is valued at billions of dollars globally. For more information, visit the company’s newsroom at https://nnw.fm/BEAT.
The conference call is scheduled for May 13, 2026, at 4:30 p.m. Eastern time. The full press release is available at https://ibn.fm/yN939. HeartBeam’s cleared indications for use can be found at https://www.heartbeam.com/indications.
